Kilitch Drugs (India) Limited — Important, 21-01-2025: General Updates

Kilitch Drugs (India) Ltd. has made an additional investment of USD 2,00,000 to acquire 25,092 equity shares in its foreign subsidiary, Kilitch Estro Biotech PLC. This acquisition aims to meet the working capital requirements of Kilitch Drugs. Post-acquisition, the company's holding in Kilitch Estro Biotech will increase from 67% to 78.09%. The cost of acquisition is approximately Rs. 1.73 Cr. Kilitch Estro, operational since January 2022, is involved in the manufacturing of pharmaceutical products in Ethiopia, with a turnover of Rs. 22.72 Cr for the year ending March 2024. This strategic move signals a positive outlook for Kilitch Drugs by strengthening its subsidiary’s financial position, which may enhance long-term returns on investment. Investors should monitor this development closely for its potential impact on future growth.